Appointed
Allan Reine
member of the Board of Directors
PRME ·
Prime Medicine, Inc.
The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director
Ready 8-Ks
43
Latest filing
August 6, 2026, 8:02 AM ET
Top materiality
1.00
Event mix
other_material ×19 · earnings ×14 · leadership ×4
Sentiment
13 pos · 2 neg · 28 neu
Latest earnings
reported 2026-Q2
Executive change
recent →
Recent 8-K filings for PRME
Highest-materiality recent filing
Prime Medicine CEO Gottesdiener resigns; Reine named CEO; positive CGD data; restructures to liver focus
- Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.
- Jeff Marrazzo named Executive Chair of the board.
-
Prime Medicine Q2 net loss $42.1M; IND/CTA clearances for PM577a, arbitration win for PM647
Net loss of $42.1M for Q2 2026 vs $52.6M in Q2 2025; R&D expenses $33.4M.
-
Prime Medicine wins arbitration against Beam; PM647 for AATD confirmed within Prime's field
Arbitration tribunal ruled PM647 (AATD candidate) is within Prime's 'Field' under 2019 Collaboration Agreement with Beam.
-
Prime Medicine Q1 net loss $49.1M; progress on Wilson, AATD programs
Net loss of $49.1M in Q1 2026 vs $51.9M in Q1 2025; R&D down to $34.1M.
-
Prime Medicine FY2025 net loss $201.1M; WD/AATD IND filings on track, CGD BLA planned
Net loss $201.1M for FY2025, cash $191.4M providing runway into 2027.
-
Prime Medicine Q3 net loss $50.6M; cash $227M funds into 2027; AATD candidate nominated
Net loss $50.6M vs $52.5M in Q3 2024; R&D spend $44.0M (+9% YoY) driven by license costs.
-
Prime Medicine Q2: positive CGD clinical data, $144M offering, cash runway into 2027
First clinical proof-of-concept for Prime Editing: two patients in CGD trial showed restored NADPH oxidase activity above clinical benefit threshold.
-
Prime Medicine prices $125M equity offering; net proceeds ~$120.2M for R&D
Offering of 38M shares at $3.30/share; underwriters have 30-day option for 5.7M additional shares.
-
Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.
-
Prime Medicine Q1 2025 net loss $51.9M; cash $158.3M; pipeline on track for CGD data in 2025
Net loss $51.9M (vs $45.8M Q1 2024); R&D $40.6M, G&A $13.3M.
-
AATD program targets E342K (Pi*Z) mutation in SERPINA1 gene using LNP-delivered Prime Editors.
-
Prime Medicine reports FY2024 net loss $195.9M; cash $204.5M; PM359 data in 2025
Net loss $195.9M for FY2024 vs $198.1M in FY2023; R&D expenses $155.3M.
-
Prime Medicine Q3 net loss $52.5M; BMS collaboration provides $110M upfront
Net loss of $52.5M in Q3 2024 vs. $50.7M in Q3 2023; R&D expenses $40.3M, G&A $14.1M.
-
Prime Medicine reports up to 80% gene correction in Wilson's Disease; on track for IND-enabling
GalNAc-LNP delivery of Prime Editors achieved up to 80% precise correction of ATP7B H1069Q mutation in humanized mice.
-
Prime Medicine inks $110M upfront BMS collaboration, refocuses pipeline, cash runway to H1 2026
Received $55M upfront + $55M equity investment ($5.00/share) from BMS for exclusive license to Prime Editing for ex vivo T-cell therapies.
-
Prime Medicine Q2 net loss $55.3M; FDA clears PM359 for CGD Phase 1/2 trial
FDA cleared IND for PM359 (Prime Editor for chronic granulomatous disease); Phase 1/2 trial initiating, initial data expected 2025.
-
Prime Medicine Q1 net loss $45.8M; FDA clears IND for CGD Prime Editing therapy
Net loss $45.8M (vs $39.4M Q1 2023); cash $224.2M as of March 31, 2024.
-
Prime Medicine reports FY2023 net loss of $198.1M; eyes IND/CTA for CGD in 1H 2024
Net loss widened to $198.1M in FY2023 ($121.8M in FY2022); R&D expenses $147.9M up from $86.7M.
-
Prime Medicine prices $150.9M public offering of common stock and pre-funded warrants
Offering of 19,200,001 shares at $6.25/share plus pre-funded warrants for 3,200,005 shares.
-
Prime Medicine reports preliminary cash of ~$135.2M as of Dec 31, 2023
Preliminary unaudited cash, equivalents, short-term investments, and restricted cash total ~$135.2M.
-
Prime Medicine appoints Allan Reine as CFO, effective Jan 17, 2024
Allan Reine named CFO and principal financial officer; previously CFO of Foghorn Therapeutics.
-
R&D expenses $41.0M (up 64% YoY); G&A $10.5M (up 59%); net loss widened to $50.7M from $29.4M.
-
Prime Medicine presents preclinical data on CGD correction and PASSIGE CAR-T platform at ASGCT
Prime editing corrected CGD mutation in >90% of CD34+ cells from four donors with no off-target edits detected.
-
Net loss of $39.4M for Q1 2023 vs $23.8M in Q1 2022; R&D expenses $30.9M.
-
New preclinical data in Friedrich's ataxia and cystic fibrosis show restoration of genetic function via Prime Editing.
Executive changes
Departed
Keith Gottesdiener
President, Chief Executive Officer and principal executive officer
PRME ·
Prime Medicine, Inc.
Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company
Appointed
Allan Reine
Chief Executive Officer and principal executive officer
PRME ·
Prime Medicine, Inc.
the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company
Appointed
Allan Reine
Chief Financial Officer
PRME ·
Prime Medicine, Inc.
On January 4, 2024, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Allan Reine as the Chief Financial Officer and the principal financial officer of the Company effective as of January 17, 2024.
Appointed
Jeff Marrazzo
Director
PRME ·
Prime Medicine, Inc.
On May 10, 2023, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Jeff Marrazzo as a director of the Company.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.60 · Most common event other_material